Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure

Cardiovascular Research

Volumn 93, Issue 2, 2012, Pages 252-262

  Yang, Kai Chien ^a   Jay, Patrick Y ^a   McMullen, Julie R ^b   Nerbonne, Jeanne M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Arrhythmia; Heart failure; Pathological hypertrophy; PI3K signalling

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE ALPHA; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARRHYTHMOGENESIS; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; MALE; MOUSE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; TRANSCRIPTION REGULATION; UPREGULATION;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, DILATED; ELECTROCARDIOGRAPHY; HEART FAILURE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; POTASSIUM CHANNELS; SIGNAL TRANSDUCTION;

EID: 84856163941     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr283     Document Type: Article

References (46)

1. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-1459. (Pubitemid 28522409)
2. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994;90:2534-2539. (Pubitemid 24354344)
3. Mayet J, Shahi M, McGrath K, Poulter NR, Sever PS, Foale RA et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996;28:791-796. (Pubitemid 26365520)
4. McIntyre H, Fry CH. Abnormal action potential conduction in isolated human hypertrophied left ventricular myocardium. J Cardiovasc Electrophysiol 1997;8:887-894. (Pubitemid 27329095)
5. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:379-385. (Pubitemid 23212118)
6. + currents with left ventricular hypertrophy. Circ Res 2008;102:1406-1415.
7. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
8. Yang KC, Foeger NC, Marionneau C, Jay PY, McMullen JR, Nerbonne JM. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy. J Physiol 2010;588:5015-5032.
9. Buerger A, Rozhitskaya O, Sherwood MC, Dorfman AL, Bisping E, Abel ED et al. Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 2006;12:392-398. (Pubitemid 43817587)
10. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signalling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007;104:612-617. (Pubitemid 46123073)
11. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003;100:12355-12360. (Pubitemid 37271564)
12. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 1998;274:H747-H751.
13. Harrison BC, Bell ML, Allen DL, Byrnes WC, Leinwand LA. Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice. J Appl Physiol 2002;92:313-322. (Pubitemid 34670020)
14. + currents among the left ventricular free wall of rats with ascending aortic stenosis. J Physiol Lon 2001;530:443-455. (Pubitemid 32162332)
15. Guo W, Jung WE, Marionneau C, Aimond F, Xu H, Yamada KA et al. Targeted deletion of Kv4.2 eliminates I(to,f) and results in electrical and molecular remodelling, with no evidence of ventricular hypertrophy or myocardial dysfunction. Circ Res 2005;97:1342-1350.
16. + currents. Circ Res 2002;90: 586-593. (Pubitemid 34640909)
17. Kuo HC, Cheng CF, Clark RB, Lin JJ, Lin JL, Hoshijima M et al. A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia. Cell 2001;107:801-813. (Pubitemid 34033672)
18. London B, Guo W, Pan X, Lee JS, Shusterman V, Rocco CJ et al. Targeted replacement of Kv1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of IK, slow and resistance to drug-induced QT prolongation. Circ Res 2001;88: 940-946. (Pubitemid 32441473)
19. Xu H, Barry DM, Li H, Brunet S, GuoW, Nerbonne JM. Attenuation of the slow component of delayed rectification, action potential prolongation, and triggered activity in mice expressing a dominant-negative Kv2 alpha subunit. Circ Res 1999;85:623-633. (Pubitemid 29467851)
20. Putzke C, Wemhoner K, Sachse FB, Rinne S, Schlichthorl G, Li XT et al. The acidsensitive potassium channel TASK-1 in rat cardiac muscle. Cardiovasc Res 2007;75: 59-68. (Pubitemid 46873507)
21. Zaritsky JJ, Redell JB, Tempel BL, Schwarz TL. The consequences of disrupting cardiac inwardly rectifying K(+) current (I(K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol 2001;533:697-710. (Pubitemid 32600525)
22. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
23. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80-83. (Pubitemid 26374592)
24. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329. (Pubitemid 24043180)
25. Adamson PB, Vanoli E. Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure: characteristics of a novel heart failure model in dogs with postmyocardial infarction left ventricular dysfunction. J Am Coll Cardiol 2001;37:1741-1748.
26. Rose J, Armoundas AA, Tian Y, DiSilvestre D, Burysek M, Halperin V et al. Molecular correlates of altered expression of potassium currents in failing rabbit myocardium. Am J Physiol Heart Circ Physiol 2005;288:H2077-H2087. (Pubitemid 40604090)
27. Akar FG, Tomaselli GF. Conduction abnormalities in nonischemic dilated cardiomyopathy: basic mechanisms and arrhythmic consequences. Trends Cardiovasc Med 2005;15:259-264. (Pubitemid 41437909)
28. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. Electrical remodelling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2006;290: H2098-H2107.
29. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
30. Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, Leinwand LA. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol 2001;90:1900-1908. (Pubitemid 32336476)
31. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 2004;95:717-725. (Pubitemid 39331932)
32. Vaseghi M, Shivkumar K. The role of the autonomic nervous system in sudden cardiac death. Prog Cardiovasc Dis 2008;50:404-419. (Pubitemid 351637603)
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
34. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676. (Pubitemid 26001955)
35. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-1338.
36. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
37. Philip-Couderc P, Tavares NI, Roatti A, Lerch R, Montessuit C, Baertschi AJ. Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism. Circ Res 2008;102:e20-e35. (Pubitemid 351651133)
38. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res 2004;32:W217-W221. (Pubitemid 38997333)
39. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000;19: 2537-2548. (Pubitemid 30323543)
40. Hombach V. Electrocardiogram of the failing heart. Card Electrophysiol Rev 2002;6: 209-214. (Pubitemid 35276928)
41. Dobrzynski H, Billeter R, Greener ID, Tellez JO, Chandler NJ, Flagg TP et al. Expression of Kir2.1 and Kir6.2 transgenes under the control of the alpha-MHC promoter in the sinoatrial and atrioventricular nodes in transgenic mice. J Mol Cell Cardiol 2006;41: 855-867. (Pubitemid 44635564)
42. Coats AJ. Clinical utility of exercise training in chronic systolic heart failure. Nat Rev Cardiol 2011;8:380-392.
43. Lachance D, Plante E, Bouchard-Thomassin AA, Champetier S, Roussel E, Drolet MC et al. Moderate exercise training improves survival and ventricular remodelling in an animal model of left ventricular volume overload. Circ Heart Fail 2009;2:437-445.
44. Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000;35:706-713. (Pubitemid 30167028)
45. Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992;85:2119-2131.
46. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-1450.